Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03623373
Title Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine

mantle cell lymphoma


Acalabrutinib + Bendamustine + Cytarabine + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.